SEARCH

Search Details

JIMBO Naoe
University Hospital / Diagnostic Pathology
Assistant Professor

Researcher basic information

■ Research Areas
  • Life sciences / Human pathology

Research activity information

■ Award
  • Jun. 2024 一般社団法人神緑会 田中千賀子学術奨励賞

  • Mar. 2024 令和5年度 日本病理学会 学術奨励賞

■ Paper
  • Hideto Ueki, Naoe Jimbo, Tomoaki Terakawa, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake
    BACKGROUND: The diagnosis of treatment-related neuroendocrine prostate cancer (t-NEPC) often involves a pathological assessment and immunohistochemistry (IHC) for neuroendocrine markers. Genomic alterations in RB1 and TP53 are frequently observed in NEPC and are believed to play a crucial role in the transformation of adenocarcinoma to NEPC. In this study, we examined the clinicopathologic, immunohistochemical, and genetic features of patients with t-NEPC to better understand their prognosis and diagnostic utility. METHODS: This retrospective study reviewed the records of patients diagnosed with t-NEPC at Kobe University Hospital between October 2018 and December 2022. Clinical data, including age, serum neuroendocrine marker levels, and treatment history, were collected. IHC was performed for conventional neuroendocrine markers (synaptophysin, chromogranin A, and CD56) and RB1 and p53 expression. Next-generation sequencing (NGS) was conducted using FoundationOne® CDx to identify mutations in RB1 and TP53. RESULTS: This study included 20 patients with t-NEPC. The median time from ADT initiation to development was 42.8 months. IHC revealed RB1 loss in 75% of cases and p53 abnormalities in 75% of cases. NGS identified RB1 mutations in 55% and TP53 mutations in 75% of cases. The concordance between NGS and IHC results was high, with 70% (14/20) agreement for RB1/RB1 and 80% (16/20) for p53/TP53. The immunostaining and genomic analysis of RB1/RB1 and p53/TP53 showed abnormal findings for the four negative cases for conventional neuroendocrine markers. CONCLUSIONS: This study indicated high concordance between IHC and NGS findings for RB1/RB1 and p53/TP53 in t-NEPC. We provide a comprehensive benchmark of NGS performance compared with IHC, and these findings may help increase the diagnostic sensitivity of t-NEPC.
    Sep. 2024, The Prostate, English, International magazine
    Scientific journal

  • Naoe Jimbo, Chiho Ohbayashi, Tomomi Fujii, Maiko Takeda, Suguru Mitsui, Yugo Tanaka, Tomoo Itoh, Yoshimasa Maniwa
    Sep. 2024, The Journal of Pathology: Clinical Research
    Scientific journal

  • 吉田 道彦, 柳本 泰明, 津川 大介, 秋田 真之, 藤田 千佳, 吉田 俊彦, 宗 慎一, 石田 潤, 南野 佳英, 浦出 剛史, 福島 健司, 権 英寿, 小松 昇平, 浅利 貞毅, 児玉 貴之, 木戸 正浩, 外山 博近, 神保 直江, 伊藤 智雄, 福本 巧
    日本膵・胆管合流異常研究会, Aug. 2024, 日本膵・胆管合流異常研究会プロシーディングス, 47, 16 - 16, Japanese

  • Miho Yoshida, Naoe Jimbo, Ryuko Tsukamoto, Tomoo Itoh, Kunimitsu Kawahara, Suguru Mitsui, Yugo Tanaka, Yoshimasa Maniwa
    Nov. 2023, Diagnostic Pathology
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naoe Jimbo, Chiho Ohbayashi, Maiko Takeda, Tomomi Fujii, Suguru Mitsui, Ryuko Tsukamoto, Yugo Tanaka, Tomoo Itoh, Yoshimasa Maniwa
    Considering the differences in protein expression in small cell lung carcinoma (SCLC) by molecular classification, it is likely that there are differences in morphology, but the relationship between molecular classification and morphology has not been examined. Furthermore, there are limited reports concerning this molecular classification for large cell neuroendocrine carcinoma (LCNEC) and SCLC simultaneously. Therefore, we investigated the relationship between immunohistochemistry-based molecular classification and morphology, protein expression, and clinical features of 146 consecutive resection specimens of pulmonary neuroendocrine carcinoma (NEC), focusing mainly on POU2F3, the master transcription factor involved in tuft cell generation. POU2F3-dominant SCLC (n=24) and LCNEC (n=14) showed overlap in cytomorphology, while non-POU2F3-dominant SCLC (n=71) and LCNEC (n=37) showed distinct differences in cytomorphology. In addition, POU2F3-dominant NEC exhibited significantly more abundant tumor stroma, more prominent nest formation, more frequent bronchial intraepithelial involvement, and less frequent background fibrosis than non-POU2F3-dominant NEC. Immunohistochemically, POU2F3-dominant SCLC and LCNEC were characterized by lower expression of TTF-1, CEA, and neuroendocrine markers and higher expression of bcl-2, c-Myc, and c-kit. Clinically, POU2F3-dominant NEC had a significantly better prognosis than non-POU2F3-dominant NEC for recurrence-free survival. POU2F3-dominant NEC had a higher smoking index than non-POU2F3-dominant NEC. POU2F3-dominant NEC forms a unique population, exhibiting intermediate morphologic features between SCLC and LCNEC, with distinct protein expression as tuft cell-like carcinoma. Recognition of this unique subtype may provide clues for solving the long-standing issues of NEC and appropriate therapeutic stratification. It is important to accurately identify POU2F3-expressing carcinomas by immunohistochemistry and to analyze their clinicopathological features.
    Oct. 2023, The American journal of surgical pathology, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naoe Jimbo, Chiho Ohbayashi, Tomomi Fujii, Maiko Takeda, Suguru Mitsui, Ryuko Tsukamoto, Yugo Tanaka, Tomoo Itoh, Yoshimasa Maniwa
    AIMS: Cytoplasmic p53 expression indicates a high frequency of TP53 abnormalities in gynaecological carcinoma. However, the implication of this expression in pulmonary neuroendocrine carcinoma (NEC) remains unclear. Thus, our study aimed to fill this research gap. METHODS AND RESULTS: Immunohistochemistry (IHC) of p53 was performed on 146 cases of resected small-cell lung carcinoma and large-cell NEC, and next-generation sequencing was conducted on cases showing cytoplasmic and wild-type p53 expression. IHC revealed overexpression in 57% of the cases (n = 83), complete absence in 31% (n = 45), cytoplasmic expression in 8% (n = 12) and wild-type expression in 4% (n = 6) of the cases. TP53 mutations were identified in nine of the 13 cases with available genetic analysis. The TP53 mutation rates in cases with cytoplasmic and wild-type p53 expression were 88% (seven of eight) and 40% (two of five), respectively. All seven cases showing cytoplasmic expression with TP53 mutations harboured loss-of-function type mutations: four had mutations in the DNA-binding domain, two in the nuclear localisation domain and one in the tetramerisation domain. Clinically, cases with cytoplasmic p53 expression had a poor prognosis similar to that in cases with p53 overexpression or complete absence. CONCLUSIONS: Cytoplasmic p53 expression in patients with pulmonary NEC suggests a high TP53 mutation rate, which is associated with a poor prognosis similar to that in patients with p53 overexpression or complete absence. This cytoplasmic expression should not be misidentified as a wild-type expression. This is the first report, to our knowledge, that demonstrates the implication of cytoplasmic p53 expression in pulmonary NEC.
    Oct. 2023, Histopathology, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Junichiro Hirata, Naoe Jimbo, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
    OBJECTIVE: This study retrospectively reviewed the clinical characteristics and treatment outcomes of patients with histologically diagnosed treatment-related pure small-cell neuroendocrine prostate cancer. METHODS: We retrospectively evaluated data for 13 patients with treatment-related neuroendocrine prostate cancer who were diagnosed between May 2015 and February 2022. Standardized systemic therapies of etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan were selected as sequential treatments. Cancer-specific survival and progression-free survival were evaluated as the primary endpoint. The Cox proportional hazards model was used to evaluate the relationships between treatment regimens, clinical variables, cancer-specific survival and progression-free survival. RESULTS: The median cancer-specific survival after diagnosis for all patients was 22.4 months (range 1.3-33.4 months). The median progression-free survival was 9.3 months after first-line etoposide plus cisplatin (or carboplatin) treatment (n = 13); 4.2 months after second-line amrubicin treatment (n = 4); and >15 months after third-line nogitecan treatment (n = 2). The median progression-free survival after first-line chemotherapy of the liver metastasis (-) group was 10.2 months, and that of the (+) group was 5.3 months (P = 0.015, hazard ratio = 11.6, 95% confidence interval = 1.01 - 133.7). No clinicopathological parameters were identified as significant independent predictors of cancer-specific survival in univariate analysis. CONCLUSION: Sequential chemotherapy with etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan may be helpful for patients with treatment-related pure small-cell neuroendocrine prostate cancer. Early biopsy of metastases and initiation of effective therapy is essential for patients with progressive castration-resistant prostate cancer and low prostate-specific antigen.
    Jun. 2023, Japanese journal of clinical oncology, 53(6) (6), 522 - 529, English, International magazine
    Scientific journal

  • Suguru Mitsui, Yugo Tanaka, Naoe Jimbo, Takefumi Doi, Shinya Tane, Daisuke Hokka, Yoshimasa Maniwa
    BACKGROUND: Identifying the preoperative risk factors for lymph node upstaging could contribute to the development of individualized perioperative treatment for patients with non-small cell lung cancer (NSCLC). The current study aimed to evaluate the risk factors for lymph node upstaging, including gene mutation and programmed death ligand-1 expression in patients with resectable NSCLC. METHODS: Data on the clinicopathological characteristics of patients who underwent lobectomy for clinical N0 NSCLC at our institution were collected. The clinicopathological findings of the pathological N0 and lymph node upstaging groups were then analyzed. Univariate and multivariate analyses were performed to examine the predictive factors for nodal upstaging. RESULTS: Of 291 patients, 40 had postoperative nodal upstaging (n = 25, N1; n = 15, N2). Large tumor size and high maximum standardized uptake value were significantly associated with nodal upstaging. The nodal upstaging group had a higher proportion of patients with solid adenocarcinoma and lymphatic, vascular, and pleural invasion than the pathological N0 group. Further, the nodal upstaging group had a higher proportion of patients with positive programmed death ligand-1 expression than the pathological N0 group. Univariate and multivariate analyses showed that tumor size and positive programmed death ligand-1 expression were associated with nodal upstaging. CONCLUSION: The appropriate therapeutic strategy including preoperative treatment and resection should be cautiously considered preoperatively in patients with clinical N0 NSCLC who have large tumors and positive programmed death ligand-1 expression.
    Jun. 2023, Thoracic cancer, 14(18) (18), 1774 - 1781, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • FDG-PET/CTで特徴的な所見を呈した異所性ACTH産生縦隔腫瘍とAspergillosisを合併した一例
    山中 智晴, 曽 菲比, 立花 美保, 井上 純子, 神保 直江, 野上 宗伸, 村上 卓道
    (一社)日本核医学会, 2023, 核医学, 60(Suppl.) (Suppl.), S185 - S185, Japanese

  • FDG-PET/CTで特徴的な所見を呈した異所性ACTH産生縦隔腫瘍とAspergillosisを合併した一例
    山中 智晴, 曽 菲比, 立花 美保, 井上 純子, 神保 直江, 野上 宗伸, 村上 卓道
    (一社)日本核医学会, 2023, 核医学, 60(Suppl.) (Suppl.), S185 - S185, Japanese

  • Atsuhiko Yatani, Naoko Katsurada, Takafumi Fukui, Jun Yamada, Hiroki Satoh, Chihiro Mimura, Daisuke Hazama, Masatsugu Yamamoto, Naoe Jimbo, Tomonori Tanaka, Motoko Tachihara
    Ultrathin bronchoscopy has been reported to have a higher diagnostic yield than thin bronchoscopy for small peripheral lung lesions in transbronchial biopsy under radial endobronchial ultrasonography (EBUS). However, data comparing the number of tumor cells in non-small cell lung cancer (NSCLC) are limited. We retrospectively compared the number of NSCLC tumor cells in peripheral lung lesions obtained using an ultrathin bronchoscope and a thin bronchoscope with radial EBUS between April 2020 and October 2021. In all patients, we used virtual bronchoscopic navigation (VBN) software, and guide sheaths were used in thin bronchoscopy cases. A total of 175 patients were enrolled in this study. Ultrathin bronchoscopy cases (n = 69) had lesions with a smaller diameter that are more peripherally located compared to thin bronchoscopy cases (n = 106) (median, 25.0 vs. 26.5 mm, mean bronchial generations accessed by bronchoscopy; 4.4±1.2 vs. 3.8±1.0, respectively; p<0.010). There were no significant differences in the overall diagnostic yield (ultrathin vs. thin bronchoscopy cases, 68.1% vs. 72.6%, p = 0.610) or diagnostic yield in only lung cancer cases (78.6% vs. 78.5%, p = 1.000). In histologically NSCLC cases (n = 102), the maximum number of tumor cells per slide as the primary endpoint was similar (average, 307.6±246.7 vs. 328.7±314.9, p = 0.710). The success rate of the Oncomine™ analysis did not differ significantly (80.0% vs. 55.6%, p = 0.247). The yield of NSCLC tumor cells was not different between the samples obtained by the ultrathin bronchoscope and those obtained by the thin bronchoscope.
    2023, PloS one, 18(8) (8), e0290609, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kenji Miura, Takefumi Doi, Yugo Tanaka, Daisuke Hokka, Naoe Jimbo, Tomoo Itoh, Yoshimasa Maniwa
    BACKGROUND: Myasthenia gravis (MG) is the most common paraneoplastic syndrome in thymoma. However, the association between MG and postoperative outcomes is controversial. Therefore, we examined the effect of MG on the surgical outcomes of patients with thymoma. METHODS: This study enrolled 145 consecutive patients with thymoma who underwent surgical resection at our institution between January 2000 and December 2020. The patients were classified into thymoma with MG (MG group) and without MG (non-MG group). Data about characteristics of patients, surgical outcomes, and prognostic factors were compared between the two groups. RESULTS: Of 145 patients, 47 (32%) presented with MG and 98 (68%) did not. There was no significant difference in terms of the incidence of postoperative complications, overall survival (OS), and recurrence-free survival (RFS) between the two groups. The deaths were not caused by thymoma. Among the patients aged >60 years, the MG group had a lower survival rate than the non-MG group. In the univariate analysis, age ≥60 years was a poor prognostic factor for OS, whereas in the multivariate analysis, Masaoka stage III and IV classifications were poor prognostic factors for RFS. CONCLUSION: The incidence of postoperative complications did not differ between patients with thymoma and without MG. In the MG group, age ≥60 years was a poor prognostic factor for OS. The postoperative follow-up of patients aged ≥60 years with thymoma with MG should focus on not only recurrence but also progression of diseases other than thymoma.
    Oct. 2022, Asian cardiovascular & thoracic annals, 30(8) (8), 924 - 930, English, International magazine
    Scientific journal

  • Megumi Nishikubo, Naoe Jimbo, Yugo Tanaka, Motoko Tachihara, Tomoo Itoh, Yoshimasa Maniwa
    Aug. 2022, Virchows Archiv
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Masako Yumura, Tatsuya Nagano, Naoe Jimbo, Ryota Dokuni, Tatsunori Kiriu, Yugo Tanaka, Motoko Tachihara, Tomoo Itoh, Yoshimasa Maniwa, Yoshihiro Nishimura, Kazuyuki Kobayashi
    BACKGROUND/AIM: Annexin A10 (ANXA10) is a member of the annexin family and a calcium-dependent phospholipid-binding protein. The aim of this study was to clarify the clinical significance of ANXA10 expression in lung adenocarcinoma. MATERIALS AND METHODS: ANXA10 expression was immunohistochemically examined in surgical specimens of lung adenocarcinoma obtained from 74 consecutive patients who underwent complete resection from January 2014 to December 2014. Expression of ANXA10 was down-regulated in A549 cells via siRNA transfection and the effect of ANXA10 on cell migration was assessed by the wound healing assay. Expression of ANXA10 was examined by immunocytochemistry and polymerase chain reaction. RESULTS: High ANXA10 expression was significantly correlated with poor overall survival (p=0.00705). Multivariate analysis with the Cox proportional hazard model demonstrated that ANXA10 expression was an independent prognostic factor. Cell migration was suppressed in ANXA10-down-regulated A549 cell lines. CONCLUSION: ANXA10 has a role in cancer cell migration and high ANXA10 expression is a novel prognostic marker in lung adenocarcinoma.
    Mar. 2022, Anticancer research, 42(3) (3), 1289 - 1294, English, International magazine
    Scientific journal

  • Takahiro Niikura, Takahiro Oda, Naoe Jimbo, Masato Komatsu, Keisuke Oe, Tomoaki Fukui, Tomoyuki Matsumoto, Shinya Hayashi, Takehiko Matsushita, Tomoo Itoh, Ryosuke Kuroda
    BACKGROUND: Induced membrane (IM) is the key component of Masquelet reconstruction surgery for the treatment of bone defects. IM is formed around the cement spacer and is known to secrete growth factors and osteoinductive factors. However, there is limited evidence available concerning the presence of osteoinductive factors in IM. This study aimed to investigate the existence of bone morphogenetic proteins (BMPs) in IM harvested from patients during the treatment of bone defects using the Masquelet technique. METHODS: This study involved six patients whose bone defects had been treated using the Masquelet technique. The affected sites were the femur (n = 3) and the tibia (n = 3). During the second-stage surgery, 1 cm2 pieces of IM were harvested. Histological sections of IM were immunostained with anti-BMP-4, 6, 7, and 9 antibodies. Human bone tissue served as the positive control. RESULTS: The presence of BMP-4, 6, 7, and 9 was observed in all IM samples. Further, immunolocalization of BMP-4, 6, 7, and 9 was observed in blood vessels and fibroblasts in all IM samples. Immunolocalization of BMP-4, 6, 7, and 9 was also observed in bone tissue within the IM in one sample, in which osteogenesis inside the IM was observed. CONCLUSIONS: This study showed that osteoinductive factors BMP-4, 6, 7, and 9 were present in the IM harvested from patients, providing evidence indicating that the Masquelet technique effectively contributes to healing large bone defects. Therefore, it may be possible for surgeons to omit the addition of BMPs to bone grafts, given the endogenous secretion of BMPs from the IM.
    Jan. 2022, Journal of orthopaedic surgery and research, 17(1) (1), 29 - 29, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yuichiro Yasuda, Tatsuya Nagano, Naoe Jimbo, Tatsunori Kiriu, Ratoe Suraya, Daisuke Hazama, Masatsugu Yamamoto, Yoshimasa Maniwa, Yoshihiro Nishimura, Kazuyuki Kobayashi
    BACKGROUND/AIM: Chloride intracellular channel 1 (CLIC1) is a member of the chloride channel protein family. The aim of this study was to clarify the role of CLIC1 in lung adenocarcinoma. PATIENTS AND METHODS: The expression levels of CLIC1 in 74 patients with completely resected lung adenocarcinoma were analyzed by immunohistochemistry. Overall survival was assessed in relation to the expression level of CLIC1. Moreover, in the lung cancer cell lines A549 and PC9, CLIC1 expression was inhibited by small interfering RNA. The function of CLIC1 was analyzed in these cell lines. RESULTS: High expression of CLIC1 was associated with short overall survival compared to low expression (p=0.0327). Multivariate analysis revealed that CLIC1 expression was an independent prognostic factor. Knockdown of CLIC1 inhibited cell proliferation and migration through suppression of the p38 MAPK signaling pathway in A549 and PC9 cells. CONCLUSION: CLIC1 may be a useful prognostic factor in lung adenocarcinoma.
    Jan. 2022, Anticancer research, 42(1) (1), 271 - 277, English, International magazine
    Scientific journal

  • 前立腺生検における狙撃生検及び系統的生検の有用性について 導管内癌(IDC-P)に狙撃生検は可能か?
    高橋 昂佑, 上野 嘉子, 神保 直江, 石田 貴樹, 松下 経, 中野 雄造, 山口 雷蔵, 藤澤 正人, 都築 豊徳
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP30 - 07, Japanese

  • 前立腺生検における狙撃生検及び系統的生検の有用性について 導管内癌(IDC-P)に狙撃生検は可能か?
    高橋 昂佑, 上野 嘉子, 神保 直江, 石田 貴樹, 松下 経, 中野 雄造, 山口 雷蔵, 藤澤 正人, 都築 豊徳
    (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP30 - 07, Japanese

  • 蜂巣 智也, 塚本 龍子, 吉田 美帆, 神保 直江, 芝地 朱音, 中西 大地, 大浦 季恵, 須广 佑介, 猪原 千愛, 古澤 哲嗣, 京竹 愛子, 今川 奈央子, 田中 伴典, 伊藤 智雄
    (公社)日本臨床細胞学会, Oct. 2021, 日本臨床細胞学会雑誌, 60(Suppl.2) (Suppl.2), 580 - 580, Japanese

  • Takanori Hirose, Anna Kobayashi, Sumihito Nobusawa, Naoe Jimbo
    To clarify the morphologic spectrum and molecular profiles of hybrid schwannoma/perineurioma (HSP), we investigated 15 tumors clinicopathologically and cytogenetically. HSP was classified into 2 morphologic types: mixed cellular and combined tumor types. The former comprising of 14 tumors mostly arose in the subcutaneous tissue of the extremities and the trunk of middle-aged adults. They were well-circumscribed and composed of elongated spindle-shaped tumor cells arranged in storiform and whorl patterns. Immunostaining revealed a mixed cellular proliferation of S-100 protein-positive and SOX10-positive Schwann cells and epithelial membrane antigen-positive, claudin 1-positive, and GLUT1-positive perineurial cells. During follow-up, no tumors were found to have recurred in any cases. In contrast, in the combined tumor type arising in the mediastinum of a young male with neurofibromatosis type 2, the intraneural perineurioma-like areas, characterized by small whorl-like structures, were present in plexiform schwannoma-like areas. No recurrence was noted in the case. Molecular analyses (array comparative genomic hybridization and fluorescence in situ hybridization) revealed LOH 22q in 2 tumors of 5 studied: one each of the mixed cellular and combined tumor types. Although the same diagnostic term, HSP, has been applied to both mixed and combined types, they should be separated from each other.
    Jul. 2021, Applied immunohistochemistry & molecular morphology : AIMM, 29(6) (6), 433 - 439, English, International magazine
    Scientific journal

  • Mehmet Ozgur Avincsal, Koki Kamizaki, Naoe Jimbo, Hirotaka Shinomiya, Ken-Ichi Nibu, Michiru Nishita, Yasuhiro Minami
    Ror2 (receptor tyrosine kinase like orphan receptor 2) is highly expressed in various types of cancers; in the majority of these cancers, Ror2 expression is associated with more aggressive disease states. Recently, it has been reported that Ror2 is highly expressed in human papilloma virus (HPV)‑positive head and neck squamous cell cancer (HNSCC) cell lines, presumably indicating that Ror2 plays a critical role in HPV‑related cancers. However, the function of Ror2 in HPV‑positive HNSCC is currently unknown. Here, we first examined the expression levels of Ror2 in clinical specimens from patients with HPV‑negative and HPV‑positive oropharyngeal squamous cell cancer (OPSCC) via immunohistochemical analysis. We found that Ror2 was expressed in both HPV‑negative and HPV‑positive OPSCC tissues. We then confirmed that HPV‑positive HNSCC cell line, UPCI:SCC152 cells, express Ror2 higher than HPV‑negative cell lines as previously reported. Suppressed expression of HPV E6/7 resulted in reduced expression levels of Ror2. We also revealed that Ror2 downregulation significantly inhibited the proliferation of UPCI:SCC152 cells without inducing apoptosis. Moreover, Ror2 knockdown decelerated G1/S phase progression and abrogated invasive migration of UPCI:SCC152 cells. These results provide strong evidence that E6 and/or E7 oncoproteins regulate the progression of HPV‑positive HNSCC by upregulating Ror2 expression, suggesting that Ror2 could potentially be a novel target in HPV‑related cancers.
    Jul. 2021, Oncology reports, 46(1) (1), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Suguru Mitsui, Yugo Tanaka, Kenji Kimura, Naoe Jimbo, Norio Chihara, Yoshimasa Maniwa
    Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease, occasionally accompanied by malignant tumors. Immunosuppressive therapy is the mainstay treatment for idiopathic NMOSD; no guidelines have been published for paraneoplastic NMOSD because it is rarely reported in the literature. We report a rare case of a 67-year-old man with paraneoplastic NMOSD associated with thymic carcinoid whose cells expressed aquaporin-4 antibody. After surgical resection, the patient's symptoms improved, and serum aquaporin-4 autoantibody turned negative. We believe that radiographic examination for mediastinal tumors in patients with NMOSD is necessary because thymic epithelial tumors could have a role in the pathogenesis of paraneoplastic NMOSD. After mediastinal tumor has been detected, they should be surgically resected to improve neurological symptoms.
    Apr. 2021, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takahiro Niikura, Naoe Jimbo, Masato Komatsu, Keisuke Oe, Tomoaki Fukui, Tomoyuki Matsumoto, Shinya Hayashi, Takehiko Matsushita, Yoshitada Sakai, Tomoo Itoh, Ryosuke Kuroda
    BACKGROUND: Rich vascularity of the induced membrane (IM) is important for Masquelet reconstruction surgery. The factors affecting IM vascularity are not completely understood. This study aimed to investigate these factors using histological samples of human IMs. METHODS: We retrospectively evaluated 36 patients whose bone defects were treated using the Masquelet technique. Two clinical pathologists analyzed histological sections of IM pieces (1 cm2). The number of blood vessels per 1 mm2 was counted and compared among men and women, femur or tibia, with and without free flap surgery, antibiotic impregnation to the cement, osteogenesis inside the membrane, smoking, and diabetes mellitus. The number of blood vessels within the same patient was compared among different time points. Correlation analysis was performed among blood vessel numbers and patient age, duration of cement spacer placement, and histological grading scales (inflammation, foreign body reaction, and fibrosis). RESULTS: IM formation with rich vascularity and some inflammation, foreign body reaction, and fibrosis were histologically confirmed in all patients. We found 37.4 ± 19.1 blood vessels per 1 mm2. The number of blood vessels was significantly lower in patients with than in those without free flap surgery; it was higher in patients with osteogenesis inside the IM. No significant correlations were found in any of the analyses. CONCLUSION: Sex, patient age, smoking, diabetes mellitus, femur or tibia, duration of cement spacer placement, and antibiotic impregnation to the cement did not affect IM vascularization. IM vascularization was reduced in patients with than in those without free flap surgery.
    Apr. 2021, Journal of orthopaedic surgery and research, 16(1) (1), 248 - 248, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naoe Jimbo, Hisashi Tateyama, Masato Komatsu, Takefumi Doi, Yugo Tanaka, Yoshimasa Maniwa, Tomoo Itoh
    Apr. 2021, Pathology international, 71(4) (4), 272 - 274, English, International magazine

  • Mizuho Nishio, Mari Nishio, Naoe Jimbo, Kazuaki Nakane
    The purpose of this study was to develop a computer-aided diagnosis (CAD) system for automatic classification of histopathological images of lung tissues. Two datasets (private and public datasets) were obtained and used for developing and validating CAD. The private dataset consists of 94 histopathological images that were obtained for the following five categories: normal, emphysema, atypical adenomatous hyperplasia, lepidic pattern of adenocarcinoma, and invasive adenocarcinoma. The public dataset consists of 15,000 histopathological images that were obtained for the following three categories: lung adenocarcinoma, lung squamous cell carcinoma, and benign lung tissue. These images were automatically classified using machine learning and two types of image feature extraction: conventional texture analysis (TA) and homology-based image processing (HI). Multiscale analysis was used in the image feature extraction, after which automatic classification was performed using the image features and eight machine learning algorithms. The multicategory accuracy of our CAD system was evaluated in the two datasets. In both the public and private datasets, the CAD system with HI was better than that with TA. It was possible to build an accurate CAD system for lung tissues. HI was more useful for the CAD systems than TA.
    Mar. 2021, Cancers, 13(6) (6), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Minami, Naoe Jimbo, Yugo Tanaka, Takahiro Uchida, Takeshi Okamoto, Nahoko Shimizu, Takefumi Doi, Daisuke Hokka, Tomoo Itoh, Yoshimasa Maniwa
    BACKGROUND: Fibrous bands (FBs) are one of the histological features in tumors which can be confirmed by hematoxylin and eosin (H&E)-stained slides. FBs have been reported to correlate with malignancy in various tumors. This study aimed to investigate whether the presence of FBs is associated with malignancy in thymoma. METHODS: A total of 123 consecutive patients with thymoma who underwent microscopically complete resections from January 2000 to December 2018 were enrolled into this study. H&E-stained slides of all thymoma patients were re-examined. Study patients were classified into two groups: with FBs (n = 36) and without FBs (n = 87). Clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS) were compared between the two groups. Furthermore, multivariate analyses were performed to identify whether the presence of FBs was associated with higher Masaoka stage and poor prognosis in patients with thymoma. RESULTS: The Masaoka stage was found to be higher and recurrence more likely in thymoma patients with FBs than in those without. RFS was significantly poorer in thymoma patients with FBs than in those without, although no significant difference was observed in OS between them. The presence of FBs was significantly associated with higher Masaoka stage in the multivariate analysis using logistic regression. Additionally, the presence of FBs was an independent prognostic factor for poor RFS in multivariate analysis using Cox's proportional hazards model. CONCLUSIONS: The presence of FBs in patients with thymoma was associated with higher Masaoka stage, higher recurrence rate, and poorer RFS. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Fibrous bands (FBs) are bands of fibrosis dividing tumors into different-sized irregular islands. The presence of FBs is associated with higher Masaoka stage and poor recurrence-free survival in patients with thymoma. WHAT THIS STUDY ADDS: The presence of fibrous bands might be associated with the malignant behavior of thymoma. Confirming the presence or absence of FBs may result in personalized medication for patients with thymoma.
    Feb. 2021, Thoracic cancer, 12(3) (3), 349 - 356, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Keisuke Arai, Shingo Kanaji, Daiki Okamoto, Ritsuko Maehara, Masashi Yamamoto, Tetsu Nakamura, Satoshi Suzuki, Naoe Jimbo, Yukiko Morinaga, Tomoo Itoh, Yoshihiro Kakeji
    International College of Surgeons, 2021, International Surgery, 105(1) (1), 152 - 156, English
    Scientific journal

  • Naoko Katsurada, Motoko Tachihara, Naoe Jimbo, Masatsugu Yamamoto, Junya Yoshioka, Chihiro Mimura, Hiroki Satoh, Koichi Furukawa, Takehiro Otoshi, Tatsunori Kiriu, Yuichiro Yasuda, Tomonori Tanaka, Tatsuya Nagano, Yoshihiro Nishimura
    BACKGROUND: Adequate tumor tissue is required to make the best treatment choice for non-small cell lung cancer (NSCLC). Transbronchial biopsy (TBB) by endobronchial ultrasonography with a guide sheath (EBUS-GS) is useful to diagnose peripheral lung lesions. The data of tumor cell numbers obtained by two different sizes of GSs is limited. We conducted this study to investigate the utility of a large GS kit to obtain many tumor cells in patients with NSCLC. METHODS: Patients with a peripheral lung lesion and suspected of NSCLC were prospectively enrolled. They underwent TBB with a 5.9-mm diameter bronchoscope with a large GS. When the lesion was invisible in EBUS, we changed to a thinner bronchoscope and TBB was performed with a small GS. We compared the tumor cell number prospectively obtained with a large GS (prospective large GS group) and those previously obtained with a small GS (small GS cohort). The primary endpoint was the tumor cell number per sample, and we assessed characteristics of lesions that could be obtained by TBB with large GS. RESULTS: Biopsy with large GS was performed in 55 of 87 patients (63.2%), and 37 were diagnosed with NSCLC based on histological samples. The number of tumor cells per sample was not different between two groups (658±553 vs. 532±526, estimated difference between two groups with 95% confidence interval (CI); 125 (-125-376), p = 0.32). The sample size of the large GS group was significantly larger than that of the small GS cohort (1.75 mm2 vs. 0.83 mm2, estimated difference with 95% CI; 0.92 (0.60-1.23) mm2, p = 0.00000019). The lesion involving a third or less bronchus generation was predictive factors using large GS. CONCLUSIONS: The sample size obtained with large GS was significantly larger compared to that obtained with small GS, but there was no significant difference in tumor cell number. The 5.9-mm diameter bronchoscope with large GS can be used for lesions involving a third or less bronchus generation.
    2021, PloS one, 16(10) (10), e0259236, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 田原 潤子, 田中 千賀, 松尾 秀俊, 神田 知紀, 神保 直江, 伊藤 智雄, 田中 雄悟, 眞庭 謙昌
    金原出版(株), Jan. 2021, 臨床放射線, 66(1) (1), 59 - 64, Japanese

  • Kazuyoshi Mitani, Teruya Kawamoto, Hitomi Hara, Naomasa Fukase, Yohei Kawakami, Masayuki Morishita, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Masato Komatsu, Naoe Jimbo, Ryosuke Kuroda, Toshihiro Akisue
    Chondrolipoma is, based on the limited case reports available, an extremely rare histological variant of lipoma with the proliferation of mature adipocytes containing an area of true hyaline cartilage. Chondrolipoma is characterized by adult onset and is often identified in the breast, pharynx and tongue. The current study presents a case of chondrolipoma of the finger in an 11 year-old girl. Physical examination indicated a well-defined elastic soft mass, measuring 2.5x2 cm, on the dorsal aspect of the proximal phalanx of the left middle finger. Magnetic resonance imaging (MRI) revealed a well-circumscribed lesion with heterogeneous signal intensity. On T1- and T2-weighted images, the lesion indicated a predominantly marked hyperintense signal containing linear hypointense regions, and on fat-suppressed short-tau inversion recovery sequences, the lesion indicated a predominant hypointensity, with linear regions displaying hyperintensity. Marginal excision of the tumor was performed. Histologically, the major component of the tumor was mature adipose tissue containing a limited area of mature hyaline cartilage matrix, without lipoblasts or malignancy. The postoperative course of the patient was excellent, with no local recurrence three years after surgery. To the best of our knowledge, the current study outlines the first pediatric case of chondrolipoma arising in the finger.
    Jan. 2021, Molecular and clinical oncology, 14(1) (1), 2 - 2, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Satoshi Sai, Yoshinori Imamura, Naomi Kiyota, Naoe Jimbo, Masanori Toyoda, Yohei Funakoshi, Naoko Chayahara, Yasuko Hyogo, Kei Takenaka, Hirotaka Suto, Hironobu Minami
    Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non-adipocytic soft-tissue sarcomas and is expected to be active in PAIS, is a multi-kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-α and -β presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months). In a second case with a weak expression of PDGFR-α and -β, the disease progressed rapidly on pazopanib (progression-free survival, 1.1 months). VEGFR-2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.
    Jan. 2021, Molecular and clinical oncology, 14(1) (1), 6 - 6, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ryota Dokuni, Tatsuya Nagano, Naoe Jimbo, Hiroki Sato, Tatsunori Kiriu, Yuichiro Yasuda, Masatsugu Yamamoto, Motoko Tachihara, Kazuyuki Kobayashi, Yoshimasa Maniwa, Yoshihiro Nishimura
    BACKGROUND: Recent studies have revealed that serpin peptidase inhibitor clade E member 2 (SERPINE2) is associated with tumorigenesis. However, SERPINE2 expression and its role in lung adenocarcinomas are still unknown. METHODS: The expression levels of SERPINE2 in 74 consecutively resected lung adenocarcinomas were analyzed by using immunostaining. Inhibition of SERPINE2 expression by small interfering RNA (siRNA) was detected by quantitative PCR. Cell number assays and cell apoptosis assays were performed to clarify the cell-autonomous function of SERPINE2 in A549 and PC9 lung cancer cells. RESULTS: The overall survival of patients with high SERPINE2 expression was significantly worse than that of patients with low SERPINE2 expression (P = 0.0172). Multivariate analysis revealed that SERPINE2 expression was an independent factor associated with poor prognosis (P = 0.03237). The interference of SERPINE2 decreased cell number and increased apoptosis in A549 and PC9 cells CONCLUSION: These results suggest that SERPINE2 can be used as a novel prognostic marker of lung adenocarcinoma.
    Dec. 2020, Respiratory research, 21(1) (1), 331 - 331, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Keisuke Miwa, Kensuke Matsumoto, Hiroshi Fujita, Eriko Hisamatsu, Hidekazu Tanaka, Koji Fukuzawa, Naoe Jimbo, Takeaki Shirai, Kenichi Hirata
    We report the case of a 31-year-old man with Uhl's anomaly. Echocardiography revealed severely enlarged nonfunctioning right ventricle and unusual findings of the premature opening of the pulmonary valve along with substantial forward flow during late-diastole, indicating that pulmonary circulation was largely dependent on compensatory right atrial contraction. Moreover, right-to-left shunt through the patent foramen ovale (PFO) achieved systemic circulation at the expense of severe hypoxia. During accelerated idioventricular rhythm (AIVR) accompanied by ventriculo-atrial (VA) conduction, hypoxemia deteriorated further because of an increased right-to-left shunt through the PFO. We report the case of an adult with Uhl's anomaly whose hemodynamics was largely dependent on the ventricularized right atrium and PFO. Although the unique hemodynamics contributed to his survival into adulthood, detrimental aspects manifested themselves during AIVR with VA conduction like a "double-edged sword." .
    Dec. 2020, Journal of cardiology cases, 22(6) (6), 305 - 308, English, Domestic magazine

  • 中皮腫診断におけるBAP1・MTAP等を用いた良悪判定の実際と問題点 中皮腫診断におけるBAP1・MTAPの免疫組織化学 標本作製法および染色法による影響
    塚本 龍子, 神保 直江, 京竹 愛子, 今川 奈央子, 吉田 美帆, 猪原 千愛, 古澤 智嗣, 尾崎 達司, 須广 佑介, 二反田 隆夫, 田中 伴典, 伊藤 智雄
    (公社)日本臨床細胞学会, Nov. 2020, 日本臨床細胞学会雑誌, 59(Suppl.2) (Suppl.2), 455 - 455, Japanese

  • Keiji Kurata, Hisayuki Matsumoto, Naoe Jimbo, Kimikazu Yakushijin, Katsuya Yamamoto, Mitsuhiro Ito, Yuji Nakamachi, Hiroshi Matsuoka, Jun Saegusa, Kuniaki Seyama, Tomoo Itoh, Hironobu Minami
    Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disease characterized by benign skin hamartomas, pulmonary cysts leading to spontaneous pneumothorax, and an increased risk of renal cancer. BHD syndrome is caused by germline mutations in the folliculin (FLCN) gene, a putative tumor suppressor, which result in loss of function of the folliculin protein and may cause cancer predisposition. In a 45-year-old woman with anemia, lymphadenopathy, and a history of recurrent spontaneous pneumothorax, 18F-FDG PET/CT detected diffuse and slight 18F-FDG accumulation in the bone marrow, enlarged spleen, and systemic multiple enlarged lymph nodes. Genetic examination identified a germline nonsense mutation [c.998C > G (p.Ser333*)] on exon 9 of FLCN. Pathological examination of the lymph node revealed a diffuse neoplastic proliferation of plasmacytoid lymphocytes. The neoplastic lymphoid cells were positive for CD20, CD138, and light chain kappa as per immunohistochemistry and mRNA in situ hybridization, and a MYD88 gene mutation [c.755T > C (p.L252P)] was identified. Accordingly, she was diagnosed with lymphoplasmacytic lymphoma concomitant with BHD syndrome. To the best of our knowledge, this is the first report describing the development of hematological malignancy in a patient with BHD syndrome. The FLCN mutation might contribute lymphomagenesis as an additional mutation cooperating with the MYD88 mutation.
    Aug. 2020, International journal of hematology, 112(6) (6), 864 - 870, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • KOTARO SUZUKI, TOMOAKI TERAKAWA, NAOE JIMBO, RENA INABA, YUZO NAKANO, MASATO FUJISAWA
    Anticancer Research USA Inc., Jun. 2020, Anticancer Research, 40(6) (6), 3519 - 3526
    [Refereed]
    Scientific journal

  • Masato Komatsu, Nobuyuki Yamamoto, Teruya Kawamoto, Yohei Kawakami, Hitomi Hara, Suguru Uemura, Noriyuki Nishimura, Toshihiro Akisue, Ryosuke Kuroda, Kazumoto Iijima, Naoe Jimbo, Maki Kanzawa, Kazuyoshi Kajimoto, Tomoo Itoh, Takanori Hirose
    We herein describe soft tissue tumor arising in the lower extremity of a pediatric patient. The tumor displayed a unique and wide range of histological features, sheet-like and cohesive growth pattern consisting of enlarged round to epithelioid atypical cells with a large alveolar and pseudopapillary histological architecture, focally mimicking alveolar soft part sarcoma and MiT family translocation renal cell carcinoma. Tumor cells were focally immunoreactive for cytokeratin, S-100, and EMA. RNA sequencing identified a novel in-frame NR1D1 (exon 5)-MAML1 (exon 2) gene rearrangement resulting in the formation of a putative chimeric protein containing the N-terminal C4-type zing finger domains of NR1D1 and the C-terminal MAML1 protein, which was confirmed by subsequent RT-PCR, Sanger sequencing, and FISH assay. To the best of our knowledge, NR1D1-MAML1 fusion has not yet been described in any neoplasms, suggesting the emergence of a novel tumor entity.
    May 2020, Virchows Archiv : an international journal of pathology, 477(6) (6), 891 - 895, English, International magazine
    [Refereed]
    Scientific journal

  • 木谷 美湖野, 江崎 諒, 鷲尾 健, 小野 竜輔, 齊藤 泰之, 神保 直江, 錦織 千佳子
    (株)医学書院, May 2020, 臨床皮膚科, 74(6) (6), 423 - 429, Japanese

  • Kazuhiro Minami, Naoe Jimbo, Yugo Tanaka, Hiroyuki Ogawa, Daisuke Hokka, Wataru Nishio, Masahiro Yoshimura, Tomoo Itoh, Yoshimasa Maniwa
    BACKGROUNDS AND OBJECTIVES: Recent studies have suggested that insulinoma-associated protein 1 (INSM1) is a useful marker for pathological diagnosis of pulmonary neuroendocrine tumors. In the present study, we investigated the association between INSM1 expression and prognosis in patients with pulmonary high-grade neuroendocrine carcinomas (HGNEC) and assessed the usefulness of INSM1 as a prognostic biomarker in these patients. METHODS: Seventy-five consecutive patients with HGNEC who underwent complete surgical resections from January 2000 to December 2018 were enrolled in this study. We classified these patients into two groups: the INSM1-positive group (n = 59) and INSM1-negative group (n = 16). We compared the clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS) between the groups. In addition, we performed univariate and multivariate analyses to identify the prognostic factors associated with postoperative survival. RESULTS: Significant differences in tumor diameter and vascular invasion between the groups were found. OS and RFS were significantly poorer in the INSM1-positive group than in the INSM1-negative group. Univariate and multivariate analyses revealed that INSM1 expression was the strongest predictor of poor prognosis for OS and RFS. CONCLUSIONS: INSM1 expression had the greatest influence on the prognosis in patients with HGNEC and may be a prognostic biomarker in these patients.
    Apr. 2020, Journal of surgical oncology, 122(2) (2), 243 - 253, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naoe Jimbo, Kunimitsu Kawahara, Ryuko Tsukamoto, Kazuhiro Minami, Yugo Tanaka, Yoshimasa Maniwa, Tomoo Itoh
    Lead, Apr. 2020, Pathology international, English, International magazine
    [Refereed]

  • Masato Komatsu, Teruya Kawamoto, Maki Kanzawa, Yohei Kawakami, Hitomi Hara, Toshihiro Akisue, Ryosuke Kuroda, Hayate Nakamura, Daisuke Hokka, Naoe Jimbo, Tomoo Itoh, Takanori Hirose
    Soft tissue myoepithelial tumors are very rare mesenchymal tumors that are currently categorized as miscellaneous neoplasms with uncertain differentiation. Although the molecular pathogenesis of soft tissue myoepithelial tumors remains unclear, EWSR1 gene fusions with a variety of partner genes are regarded as one of the major pathogenic driver events in these tumors. We herein present a case of a deep soft tissue malignant myoepithelial tumor arising in the thigh with multiple pulmonary metastases. This tumor displayed diverse and unique histological features, namely, an epithelioid glandular growth pattern, pseudorosette-like formation, and a diffuse nest and cord-like pattern within an abundant myxoid matrix. Next-generation RNA sequencing identified a novel fusion transcript, in which the in-frame junctional reads contained exon 9 of EWSR1 and exon 2 of VGLL1, resulting in the formation of a putative chimeric protein with the N-terminal transcriptional activation domain of EWSR1 and C-terminal full length of the VGLL1 protein. EWSR1-VGLL1 fusion has not been described in neoplasm before. Further molecular and functional experiments on the present EWSR1-VGLL1 fusion gene are required to elucidate its tumorigenic effect.
    Apr. 2020, Genes, chromosomes & cancer, 59(4) (4), 249 - 254, English, International magazine
    [Refereed]
    Scientific journal

  • 嚢胞性病変を伴う肺硝子化肉芽腫の1症例(A Case of Pulmonary Hyalinizing Granulomas with Cystic Lesion)
    田中 伴典, 大谷 恭子, 酒井 康裕, 山崎 隆, 伊藤 智雄, 神保 直江
    (一社)日本病理学会, Mar. 2020, 日本病理学会会誌, 109(1) (1), 419 - 419, English

  • Kazuhiro Minami, Naoe Jimbo, Yugo Tanaka, Daisuke Hokka, Yoshifumi Miyamoto, Tomoo Itoh, Yoshimasa Maniwa
    Malignant pleural mesothelioma (MPM), associated with unfavorable outcomes, is closely associated with asbestos exposure. Early detection and treatment are critical to prolong survival of patients with MPM because of the rapid progression and resistance to treatment. The recently defined malignant mesothelioma in situ (MIS) has been gaining increasing attention with advances in genome-based methods including fluorescence in situ hybridization (FISH) as well as immunohistochemistry. We herein report the case of a MIS in a 73-year-old male with a history of asbestos exposure presenting with massive pleural effusion in the right thoracic cavity. Video-assisted thoracoscopic surgery with pleural biopsy of the right side revealed a single layer of atypical mesothelial cells without invasive lesions by hematoxylin and eosin staining. However, these mesothelial cells exhibited a loss of methylthioadenosine phosphorylase (MTAP) by immunohistochemistry and homozygous deletion of CDKN2A (p16) by FISH, leading to the diagnosis of MIS.
    Lead, Mar. 2020, Virchows Archiv : an international journal of pathology, 476(3) (3), 469 - 473, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Atsusuke Yatomi, Shumpei Mori, Hirotaka Kawauchi, Ayu Shono, Shinsuke Shimoyama, Hidekazu Tanaka, Takaichi Okano, Takeshi Inoue, Naoe Jimbo, Akio Morinobu, Ken-Ichi Hirata
    A 72-year-old woman was referred to our institution with decompensated congestive heart failure owing to subacute severe aortic regurgitation and mitral regurgitation. Her blood sample tested positive for myeloperoxidase anti-neutrophil cytoplasmic antibody (ANCA). Cardiac computed tomography revealed abnormal thickening and shortening of the aortic valvar leaflets as well as wall thickening of the sinuses of Valsalva. Based on the diagnosis of ANCA-associated vasculitis, predominantly involving the aortic root, prednisolone administration was initiated, which failed to improve the valvar dysfunction. The patient underwent aortic root replacement and mitral annuloplasty. Histopathology confirmed severe inflammation involving both the aortic valvar sinuses and leaflets.
    Mar. 2020, Internal medicine (Tokyo, Japan), 59(5) (5), 663 - 671, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kenji Kimura, Hiroyuki Ogawa, Naoe Jimbo, Daisuke Hokka, Yugo Tanaka, Yoshimasa Maniwa
    Mediastinal leiomyosarcoma is an aggressive tumor that primarily occurs in the posterior mediastinum. A bronchogenic cyst is a benign lesion that often develops in the mediastinum close to the thoracic trachea and has been reported to be the origin of certain malignancies. The present study reports an extremely rare case of an anterior mediastinal leiomyosarcoma that was considered to have originated from a bronchogenic cyst. An 82-year-old woman complained of chest pain, presenting an abnormal 70 mm mass shadow in the anterior mediastinum of a chest CT scan. Mediastinal tumor resection was performed and the tumor was diagnosed as a leiomyosarcoma. As the tumor was located adjacent to a bronchogenic cyst, it was considered to have originated from the remnant tissue of the cyst. Recurrent lesions were noted in the right lower lobe on CT scan 24 months after surgery.
    Mar. 2020, Molecular and clinical oncology, 12(3) (3), 244 - 246, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Suzuki, Tomoaki Terakawa, Shiro Kimbara, Masanori Toyoda, Naoe Jimbo, Yuzo Nakano, Hironobu Minami, Masato Fujisawa
    Jan. 2020, Clinical genitourinary cancer, English, International magazine
    [Refereed]

  • Nanako Miwa, Tatsuya Nagano, Naoe Jimbo, Ryota Dokuni, Tatsunori Kiriu, Chihiro Mimura, Yuichiro Yasuda, Masahiro Katsurada, Masatsugu Yamamoto, Motoko Tachihara, Yugo Tanaka, Kazuyuki Kobayashi, Tomoo Itoh, Yoshimasa Maniwa, Yoshihiro Nishimura
    Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is expressed at high levels in bone marrow cells and has a crucial role in innate immunity. Current studies indicate that CARD9 also plays a key role in tumor progression, but there are few reports on the role of CARD9 in lung cancer. The aim of this study was to clarify the role of CARD9 in lung adenocarcinoma. Patients and Methods: Lung adenocarcinoma tumor samples from 74 patients who underwent complete resection at Kobe University Hospital from January 2014 to December 2014 were analyzed by immunohistochemistry. The role of CARD9 in cancer cells was analyzed using lung cancer cell lines treated with CARD9 siRNA. Results: High expression of CARD9 was observed in 32.4% of tumors, and compared to low expression of CARD9, high expression was associated with poorer overall survival (P = 0.0365). Univariate and multivariate analyses showed that high expression of CARD9 was an independent prognostic factor. Knockdown of CARD9 in lung adenocarcinoma cells inhibited proliferation but did not increase apoptosis. In addition, CARD9 activated the NF-κB pathway in a lung adenocarcinoma cell line. Conclusion: CARD9 was shown to be an independent prognostic factor of poor outcome for lung cancer and may represent a molecular target for treatment.
    2020, OncoTargets and therapy, 13, 9005 - 9013, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 辻本 泰貴, 中村 友昭, 山本 直希, 高吉 倫史, 山本 雅昭, 福岡 秀規, 佐藤 伊都子, 大橋 千裕, 田中 雄悟, 眞庭 謙昌, 稲葉 礼奈, 神保 直江, 小川 渉, 高橋 裕, 千原 和夫
    (一社)日本内分泌学会, Jan. 2020, 日本内分泌学会雑誌, 95(3) (3), 1142 - 1142, Japanese

  • Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma.
    Anna Kobayashi, Toshiko Sakuma, Masayo Fujimoto, Naoe Jimbo, Takanori Hirose
    Nov. 2019, Applied immunohistochemistry & molecular morphology : AIMM, 27(10) (10), 758 - 763
    [Refereed]

  • MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
    Naoe Jimbo, Masato Komatsu, Tomoo Itoh, Takanori Hirose
    Lead, Nov. 2019, Cardiovascular pathology, 43, 107142
    [Refereed]

  • Naoko Katsurada, Hisashi Ohnishi, Miho Ikeda, Naoe Jimbo, Yukihisa Hatakeyama, Kayoko Okamura
    Primary pleural synovial sarcoma is a malignant tumour and thought to be more aggressive than synovial sarcoma which occurs in extremities. Its treatment strategy has not been fully established because of its rarity. We report a primary pleural synovial sarcoma case which achieved a long-term survival with repeated surgery of recurrent pleural tumour. A 39-year-old man presented with a gradually enlarged tumour in the left hemithorax. The tumour was resected and diagnosed as primary pleural synovial sarcoma. The tumour was slowly growing and repeatedly recurrent in the left pleura. The surgical resections for the recurrent tumours were performed 6 years and 11 years after the initial surgery. Intriguingly, recurrent tumour which developed after second surgery exhibited temporally spontaneous regression. Our patient remains alive 12 years after the initial surgery. Repeated resection of metastatic lesion can achieve long survival in primary pleural synovial sarcoma.
    Nov. 2019, Respirology case reports, 7(8) (8), e00480, English, International magazine
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Minami, Yugo Tanaka, Hiroyuki Ogawa, Naoe Jimbo, Wataru Nishio, Masahiro Yoshimura, Tomoo Itoh, Yoshimasa Maniwa
    BACKGROUND: The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). METHODS: From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small-sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small-sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small-sized SCLC (sSCLC). RESULTS: A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small-sized triple-positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small-sized nontriple-positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence-free survival (RFS) and tumor-specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP. CONCLUSIONS: The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC.
    Nov. 2019, Thoracic cancer, 10(11) (11), 2152 - 2160, English, International magazine
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • 神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌10例の臨床的検討
    寺川 智章, 坂本 茉莉子, 岡村 泰義, 板東 由加里, 鈴木 光太郎, 原 琢人, 古川 順也, 原田 健一, 日向 信之, 中野 雄造, 藤澤 正人, 神保 直江
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P103 - 7, English

  • Kiyoko Koyama, Naoko Katsurada, Naoe Jimbo, Motoko Tachihara, Daisuke Tamura, Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Hiroshi Kamiryo, Kazuyuki Kobayashi, Tomoo Itoh, Yoshihiro Nishimura
    Transformation to small cell lung cancer is one phenomenon of acquired resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in ALK rearrangement-positive non-small cell lung cancer (NSCLC). Few case reports have focused on other types of histological transformation. We report a case of transformation of ALK rearrangement-positive adenocarcinoma to NSCLC with neuroendocrine differentiation during alectinib therapy. A 36-year-old woman presented with a tumor in the left lower lobe and bone metastases. She was diagnosed with ALK rearrangement-positive adenocarcinoma by histopathology of the primary tumor. Alectinib had been effective for 8 months before new lesions appeared. Histopathological re-examination of a recurrent tumor revealed poorly differentiated carcinoma with insulinoma-associated protein 1 (INSM1) expression, which remained ALK-positive. Expression of CD133, BCL-2, and SOX2 was positive in comparison to the initial tumor. Expression of SOX2 became more strongly positive than it was before treatment. The immunohistochemical findings of these markers associated with cancer stem-like cells and/or neuroendocrine differentiation suggest that cancer stem cells play a role in the mechanisms of histological transformation and acquired resistance of ALK rearrangement-positive cancer. To our knowledge, this is the first report to suggest an association between cancer stem-like cells and histological transformation in ALK rearrangement-positive lung cancer.
    May 2019, Pathology international, 69(5) (5), 294 - 299, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yusuke Shiraishi, Tomoaki Terakawa, Naoe Jimbo, Katsumi Shigemura, Nobuyuki Hinata, Masato Fujisawa
    Feb. 2019, International journal of urology : official journal of the Japanese Urological Association, 26(2) (2), 313 - 314, English, International magazine
    [Refereed]
    Scientific journal

  • Gene Expression and Methylation Analysis in Melanomas and Melanocytes From the Same Patient: Loss of NPM2 Expression Is a Potential Immunohistochemical Marker for Melanoma
    Fujiwara Susumu, Nagai Hiroshi, Jimbo Haruki, Jimbo Naoe, Tanaka Tomoyo, Inoie Masukazu, Nishigori Chikako
    DNA methylation is considered the primary epigenetic mechanism underlying the development of malignant melanoma. Since DNA methylation can be influenced by environmental factors, it is preferable to compare cancer and normal cells from the same patient. In order to compare the methylation status in melanoma tissues and melanocytes from the same individuals, we employed a novel epidermal sheet cultivation technique to isolate normal melanocytes from unaffected sites of melanoma patients. We also analyzed primary and metastatic melanoma samples, three commercially available melanocytes, and four melanoma cell lines. Cluster analysis of DNA methylation data classified freshly isolated melanomas and melanocytes into the same group, whereas the four melanoma cell lines were clustered together in a distant clade. Moreover, our analysis discovered methylation at several novel loci (KRTCAP3, AGAP2, ZNF490), in addition to those identified in previous studies (COL1A2, GPX3); however, the latter two were not observed in fresh melanoma samples. Subsequent studies revealed that NPM2 was hypermethylated and downregulated in melanomas, which was consistent with previous reports. In many normal melanocytes, NPM2 showed distinct immunohistochemical staining, while its expression was lost in malignant melanoma cells. In particular, intraepithelial lesions of malignant melanoma, an important challenge in clinical practice, could be distinguished from benign nevi. The present findings indicate the importance of using fresh melanoma samples, not melanoma cell lines and melanocytes in epigenetic studies. In addition, NPM2 immunoreactivity could be used to differentiate melanomas from normal melanocytes or benign disease.
    Frontiers Media, Jan. 2019, Frontiers in Oncology, 8(8) (8), 675 - 675, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Gentaro Yamasaki, Mitsumasa Okano, Kazuhiko Nakayama, Naoe Jimbo, Sho Sendo, Naoki Tamada, Kenta Misaki, Yuto Shinkura, Kenichi Yanaka, Hidekazu Tanaka, Kengo Akashi, Akio Morinobu, Hiroshi Yokozaki, Noriaki Emoto, Ken-Ichi Hirata
    Rheumatoid vasculitis is a rare etiology for pulmonary hypertension (PH) in patients with connective tissue disease. We encountered a case of acute PH crisis in a case with rheumatoid vasculitis eight months after undergoing adalimumab reduction. Since no repetition of arthralgia occurred after the adalimumab reduction, we decided to not increase the dose of adalimumab. However, hemodynamic collapse thereafter developed and even though steroid pulse therapy was administered, the patient nevertheless died. The autopsy showed clusters of acute and chronic inflammation around the remodeled pulmonary arteries along with micro-thrombi in the vessel lumen. We should consider the possibility of critical worsening of PH as a phenotype of vasculitis related to immunosuppressive therapy reduction.
    2019, Internal medicine (Tokyo, Japan), 58(4) (4), 593 - 601, English, Domestic magazine
    [Refereed]
    Scientific journal

  • Katsurada Naoko, Tachihara Motoko, Jimbo Naoe, Koyama K, Nakata K, Nagano Tatsuya, Yamamoto Masatsugu, Otera Hiroshi, Kobayashi Kazuyuki, Nishimura Yoshihiro
    Hypertrophic pulmonary osteoarthropathy (HPO) is a paraneoplastic syndrome characterized by digital clubbing, arthritis, and periostitis. Tumor removal usually leads to the resolution of these symptoms. We herein report the efficacy of crizotinib treatment for treating the symptoms of HPO associated with c-ros oncogene 1 receptor tyrosine kinase (ROS1)-rearranged lung cancer. A 71-year-old woman presented with a pulmonary tumor and arthritis. She was diagnosed with a ROS1-rearranged lung adenocarcinoma [stage IIIB (cT4N2M0) ] with HPO. Crizotinib dramatically reduced the tumor size and resolved the symptoms. After two months of crizotinib treatment, she underwent lobectomy, and a pathological evaluation revealed ypstage IIIA (ypT3a, ypN1). Crizotinib treatment was effective for reducing the tumor size and improving the symptoms of HPO.
    Jan. 2019, Intern Med, 58(10) (10), 1467 - 1471, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Low-grade fibromyxoid sarcoma(Evans tumor)の臨床病理学的検討 診断におけるFISHの有用性
    深瀬直政, 藤田郁夫, Kawamoto Teruya, 藤本卓也, 佐久間淑子, 廣瀬隆則, 神保直江, 伊藤智雄, Hara Hitomi, 秋末敏宏, 黒田良祐
    Jun. 2018, 日本整形外科学会雑誌, 92(6号) (6号), S1385, Japanese
    [Refereed]
    Research society

  • Mehmet Ozgur Avincsal, Naoe Jimbo, Kohei Fujikura, Hirotaka Shinomiya, Naoki Otsuki, Koichi Morimoto, Tatsuya Furukawa, Naruhiko Morita, Ritsuko Maehara, Tomoo Itoh, Ken-Ichi Nibu, Yoh Zen
    AIMS: We recently reported that a small subset (7%) of oesophageal squamous cell carcinomas completely lacking SOX2 expression had unique clinicopathological features and a dismal prognosis. The aim of the present study was to elucidate whether the findings obtained in oesophageal cancers are applicable to hypopharyngeal squamous cell carcinomas (HPSCCs) or oropharyngeal squamous cell carcinomas (OPSCCs). METHODS AND RESULTS: The study cohort consisted of consecutive patients with HPSCC (n = 130) and OPSCC (n = 65) who underwent surgery without preoperative therapy. On immunostaining, SOX2 was almost entirely negative in 10 of 130 HPSCCs (8%) and seven of 65 OPSCCs (11%). No significant differences were observed in clinicopathological features, including p16 status, between SOX2-positive and SOX2-negative cancers. However, patients with SOX2-negative HPSCC had significantly worse overall and recurrence-free survival than those with SOX2-positive HPSCC, whereas such a prognostic relationship was not confirmed in patients with OPSCC. In a multivariate analysis, the loss of SOX2 expression appeared to be an independent poor prognostic factor for patients with HPSCC. In a sequencing analysis, no mutation was found in SOX2. As SOX2 is known to contain an extensive CpG island before the transcription start site, methylation-specific polymerase chain reaction for the SOX2 promoter was performed. Methylated alleles were found in nine of 10 SOX2-negative HPSCCs but in none of SOX2-positive HPSCCs. CONCLUSIONS: Similarly to oesophageal cancers, a small subset (8%) of HPSCCs characteristically almost completely lacking SOX2 expression appeared to be aggressive neoplasms with high recurrence rates. Promoter hypermethylation was determined to be a major mechanism underlying epigenetic SOX2 silencing.
    Apr. 2018, Histopathology, 72(5) (5), 826 - 837, English, International magazine
    [Refereed]
    Scientific journal

  • PRR11 immunoreactivity is a weak prognostic factor in non-mucinous invasive adenocarcinoma of the lung.
    Y Sakai, C Ohbayashi, E Yanagita, N Jimbo, K Kajimoto, T Sakuma, T Hirose, M Yoshimura, Y Maniwa, T Itoh
    INTRODUCTION: Proline-rich protein 11 (PRR11) functions in the progression of cell cycle, and silencing the PRR11 gene in lung cancer cells results in the inhibition of cellular proliferation, cell cycle progression, cell migration, invasion and colony formation. PRR11 may therefore be a therapeutic target in lung cancer. MATERIALS AND METHODS: Microarrays of surgical specimens of non-mucinous invasive adenocarcinoma of the lung, from 346 subjects that were not given preoperative therapy, were autoimmunostained with PRR11 and, except for trace and pseudo-positivity, assessed as "positive" at any proportion and intensity. RESULTS: PRR11 immunoreactivity demonstrated a tendency to associate with an aggressive phenotype (tumor size, vascular invasion, and adjuvant therapy) and some effect on overall survival (Hazard ratio 1.51). CONCLUSIONS: PRR11 may be a weak prognostic indicator of overall survival of patients with non-mucinous invasive adenocarcinoma of the lung.
    Sep. 2017, Pathologica, 109(3) (3), 133 - 139, English, International magazine
    [Refereed]
    Scientific journal

  • Naoe Jimbo, Takashi Nishigami, Masayuki Noguchi, Hiroko Iijima, Seiichi Hirota, Takuma Tajiri, Takeshi Inoue, Takanori Hirose, Tomoo Itoh, Yoh Zen
    Lead, Mar. 2017, HUMAN PATHOLOGY, 61, 41 - 48, English
    [Refereed]
    Scientific journal

  • 肝血管筋脂肪腫におけるTFE3遺伝子異常
    神保直江, 西上隆之, 野口雅之, 廣田誠一, 田尻琢磨, 井上健, 全陽, Hirose Takanori, 伊藤智雄
    Apr. 2016, 日本病理学会会誌, 105(1号) (1号), 385, Japanese
    [Refereed]
    Scientific journal

  • Mehmet Ozgur Avincsal, Kyoko Otani, Maki Kanzawa, Kohei Fujikura, Naoe Jimbo, Yukiko Morinaga, Takanori Hirose, Tomoo Itoh, Yoh Zen
    Mar. 2016, PATHOLOGY INTERNATIONAL, 66(3) (3), 158 - 163, English
    [Refereed]
    Scientific journal

  • Pathological Complete Response after Preoperative Chemotherapy with a Regimen Containing Trastuzumab in Esophagogastric Junction Adenocarcinoma
    KeisukeArai, ShingoKanaji, DaikiOkamoto, RitsukoMaehara, MasashiYamamoto, TetsuNakamura, SatoshiSuzuki, Jimbo Naoe, YukikoMorinaga, TomooItoh, dYoshihiroKakeji
    2016, Int Surg, English
    [Refereed]
    Scientific journal

  • N Itoguchi, T Nakagawa, Y Murata, D Li, A Shiba-Ishii, Y Minami, M Noguchi
    OBJECTIVE: Brushing or washing cytology taken at bronchoscopy is a standard diagnostic procedure for lung cancer. The present study evaluated the sensitivity of immunocytochemical diagnosis of lung cancer using bronchial washing materials. METHODS: We collected bronchial washing samples taken at bronchoscopy between July 2012 and July 2013 at Tsukuba University Hospital and studied 106 cases that were finally diagnosed as lung cancer. We collected exfoliated cells using a thin-layer advanced cytology assay system (TACAS(™)) and performed cytological diagnosis using Papanicolaou staining. As controls, we randomly selected 30 tumour-negative cases from among samples collected during the same period. Using these materials, we also examined the expression of stratifin (14-3-3 sigma) (n = 92) and OCIAD2 ovarian immunoreactive antigen domain 2) (n = 106) by immunocytochemistry, as these are considered to be broad spectrum immune markers for lung adenocarcinoma including early invasive lung adenocarcinoma. RESULTS: Using Papanicolaou staining, 52 out of 106 lung cancers (49.1%) were diagnosed as positive. However, positivity was increased to 63.0% by immunocytochemistry using anti-stratifin or anti-OCIAD2 antibodies. Biopsies were taken in 103/106 cases and cancer was diagnosed in 60/103, (58.3%). The sensitivity of stratifin or OCIAD2 was significantly higher than that of Papanicolaou staining (P = 0.027), but immunocytochemistry detected false-positive cells in 3/30 cases (10%) for stratifin and 2/30 cases (7%) for OCIAD2. CONCLUSION: Immunocytochemical staining for stratifin and OCIAD2 improved diagnostic sensitivity for lung cancers but diagnostic specificity was lower than that for cytology alone. The immunostains carried up to a 10% risk of a false-positive result and therefore positive staining must be confirmed by morphological evidence of malignancy.
    Lead, Dec. 2015, Cytopathology : official journal of the British Society for Clinical Cytology, 26(6) (6), 354 - 61, English, International magazine
    [Refereed]

  • 原発性肺癌1464例に対するNUT染色の検討
    Sakai Yasuhiro, 大谷恭子, 神保直江, 佐久間淑子, 服部剛弘, 島田天美子, 浦田佳子, 里内美弥子, 根來俊一, 多根健太, 西尾渉, 吉村雅裕, 橋本知久, 竹中大祐, 足立秀治, 大林千穂
    Oct. 2015, 肺癌, 55(5号) (5号), 554, Japanese
    Research society

  • 肺癌と鑑別を要した炎症性結節の1例
    大谷 恭子, 神保 直江, 酒井 康裕, 寺下 智美, 三輪 菜々子, 西村 春佳, 國政 啓, 徳永 俊太郎, 畠山 由記久, 永野 達也, 新家 治子, 堀 朱矢, 櫨木 暢子, 中田 恭介, 田村 大介, 立原 素子, 上領 博, 小林 和幸, 西村 善博, 内田 孝宏, 大隅 宏通, 清水 奈保子, 奥田 祐亮, 小川 裕行, 法華 大助, 田根 慎也, 田中 雄悟, 眞庭 謙昌, 神山 久信, 大野 良治
    (NPO)日本肺癌学会, Aug. 2015, 肺癌, 55(4) (4), 317 - 317, Japanese

  • Ei-ichiro Takaoka, Jun Miyazaki, Tomokazu Kimura, Takahiro Kojima, Koji Kawai, Yoshihiko Murata, Naoe Itoguchi, Yuko Minami, Takako Nakamura, Katsuya Honda, Hiroyuki Nishiyama
    A 44-year-old woman was admitted to the hospital for asymptomatic gross hematuria. At the age of 28, she underwent transplantation of a kidney from her father for end-stage renal disease secondary to rapidly progressive glomerulonephritis. She resumed peritoneal dialysis when the allograft kidney stopped functioning at the age of 42. Dialysis was continued for the next 2 years, when the hematuria occurred and she was readmitted. Radiologic evaluation and transurethral resection of the bladder tumor revealed a tumor of the renal pelvis of the allograft kidney (cT3N0M0) and multiple bladder tumors (cT1N0M0). Total cystectomy and allograft nephroureterectomy were performed. Histopathological examinations revealed high grade urothelial carcinoma in the renal pelvis of the allograft kidney (pT3) and native bladder (pT1). Fluorescence in situ hybridization of both specimens demonstrated that the renal pelvic tumors and bladder cancer possessed XY karyotypes. These results indicated that the urothelial carcinoma developed de novo in the renal pelvis of the allograft kidney and was implanted into the recipient's native bladder.
    Apr. 2014, Japanese journal of clinical oncology, 44(4) (4), 366 - 9, English, International magazine
    [Refereed]
    Scientific journal

  • Hirofumi Sakurai, Yuko Morishima, Naoe Itoguchi, Shigeo Ohtsuka, Ichiro Yamadori, Takahiro Oto, Yukio Ishii, Tohru Sakamoto, Masayuki Noguchi, Nobuyuki Hizawa
    Aug. 2013, Transplantation, 96(4) (4), e29-30, English, International magazine
    [Refereed]

■ MISC
  • 神保 直江, 吉田 美帆, 塚本 龍子, 南 和宏, 田中 雄悟, 眞庭 謙昌, 河原 邦光, 田中 伴典, 伊藤 智雄
    (公社)日本臨床細胞学会, May 2021, 日本臨床細胞学会雑誌, 60(Suppl.1) (Suppl.1), 138 - 138, Japanese

  • 吉田 美帆, 塚本 龍子, 神保 直江, 大浦 季恵, 須广 佑介, 猪原 千愛, 古澤 哲嗣, 今川 奈央子, 伊藤 智雄
    (公社)日本臨床細胞学会, May 2021, 日本臨床細胞学会雑誌, 60(Suppl.1) (Suppl.1), 227 - 227, Japanese

  • 術後補助化学療法施行肺腺癌におけるOCT3の発現と患者予後との関連
    道本 貴則, 井筒 雅大, 大崎 博之, 鴨志田 伸吾, 永野 達也, 桐生 辰徳, 西村 義博, 眞庭 謙昌, 神保 直江, 伊藤 智雄
    (一社)日本病理学会, Mar. 2021, 日本病理学会会誌, 110(1) (1), 284 - 284, Japanese

  • 局所的に肺線維性瘢痕に似た通常型間質性肺炎パターン(Localized Lung Fibrotic Scar mimicking Usual Interstitial Pneumonia like Pattern)
    田中 伴典, 兵頭 俊記, 神保 直江, 石田 佳央理, 伊藤 智雄
    (一社)日本病理学会, Mar. 2021, 日本病理学会会誌, 110(1) (1), 293 - 293, English

  • 局所的にMTAP lossとp16ホモ欠失が見られた胸膜mesothelioma in situの1症例
    神保 直江, 平社 亜沙子, 田中 伴典, 吉田 美帆, 塚本 龍子, 伊藤 智雄
    (一社)日本病理学会, Mar. 2021, 日本病理学会会誌, 110(1) (1), 296 - 296, Japanese

  • 脾EBウイルス関連炎症性偽腫瘍が考えられた一例
    中西 亨明, 神保 直江, 上原 慶一郎, 伊藤 智雄
    (一社)日本病理学会, Mar. 2021, 日本病理学会会誌, 110(1) (1), 360 - 360, Japanese

  • 塚本 龍子, 神保 直江, 京竹 愛子, 今川 奈央子, 吉田 美帆, 猪原 千愛, 古澤 智嗣, 尾崎 達司, 須广 佑介, 二反田 隆夫, 田中 伴典, 伊藤 智雄
    (公社)日本臨床細胞学会, Nov. 2020, 日本臨床細胞学会雑誌, 59(Suppl.2) (Suppl.2), 455 - 455, Japanese

  • 今川 奈央子, 塚本 龍子, 須广 佑介, 尾崎 達司, 猪原 千愛, 古澤 哲嗣, 京竹 愛子, 吉田 美帆, 神保 直江, 伊藤 智雄
    (公社)日本臨床細胞学会, May 2020, 日本臨床細胞学会雑誌, 59(Suppl.1) (Suppl.1), 311 - 311, Japanese

  • 浦瀬 靖代, 上野 嘉子, 神田 知紀, 祖父江 慶太郎, 小川 悟史, 稲場 礼奈, 神保 直江, 村上 卓道
    金原出版(株), May 2020, 臨床放射線, 65(5) (5), 487 - 490, Japanese

  • 神保 直江, 廣瀬 隆則
    (株)文光堂, Mar. 2020, 病理と臨床, 38(3) (3), 243 - 248, Japanese

  • 右側頭葉に発生したhistiocytic sarcomaの一例
    稲場 礼奈, 神澤 真紀, 神保 直江, 児玉 良典, 伊藤 智雄, 廣瀬 隆則
    (一社)日本病理学会, Mar. 2020, 日本病理学会会誌, 109(1) (1), 386 - 386, Japanese

  • 術後補助化学療法施行肺腺癌におけるATOX1の発現と患者予後との関連
    小松 由季, 大崎 博之, 鴨志田 伸吾, 永野 達也, 桐生 辰徳, 西村 善博, 眞庭 謙昌, 神保 直江, 伊藤 智雄
    (一社)日本病理学会, Mar. 2020, 日本病理学会会誌, 109(1) (1), 410 - 410, Japanese

  • 嚢胞性病変を伴う肺硝子化肉芽腫の1症例(A Case of Pulmonary Hyalinizing Granulomas with Cystic Lesion)
    田中 伴典, 大谷 恭子, 酒井 康裕, 山崎 隆, 伊藤 智雄, 神保 直江
    (一社)日本病理学会, Mar. 2020, 日本病理学会会誌, 109(1) (1), 419 - 419, English

  • Malignant mesothelioma in situと考えられた1例
    南和宏, 田中雄悟, 法華大助, 神保直江, 宮本良文, 眞庭謙昌
    2020, 日本呼吸器外科学会総会(Web), 37th

  • 井澤 良介, 南 和宏, 清水 奈保子, 土井 健史, 神保 直江, 田中 雄悟, 眞庭 謙昌
    (NPO)日本肺癌学会, Nov. 2019, 肺癌, 59(6) (6), 882 - 882, Japanese

  • アミロイド沈着により著明な石灰化を呈した前縦隔リンパ腫の1例
    松尾 秀俊, 岸田 雄治, 神田 知紀, 神保 直江, 伊藤 智雄, 田中 雄悟, 眞庭 謙昌, 村上 卓道
    (公社)日本医学放射線学会, Sep. 2019, 日本医学放射線学会秋季臨床大会抄録集, 55回, S550 - S550, Japanese

  • 骨病変を合併した非HIV患者の悪性梅毒の1例
    上田 沙紀, 西山 智司, 山田 はるひ, 福本 絢子, 錦織 千佳子, 神保 直江, 山田 陽三
    日本皮膚科学会-大阪地方会・京滋地方会, Aug. 2019, 皮膚の科学, 18(4) (4), 246 - 246, Japanese

  • 再発時に脱分化が疑われたmalignant solitary fibrous tumorの1例
    南 和宏, 田中 雄悟, 中村 速, 黒田 紗菜恵, 松本 学, 光井 卓, 酒井 秀都, 木村 賢司, 岡本 武士, 清水 奈保子, 土井 健史, 法華 大助, 眞庭 謙昌, 神保 直江, 酒井 康裕
    (NPO)日本肺癌学会, Aug. 2019, 肺癌, 59(4) (4), 426 - 426, Japanese

  • in situ主体の悪性胸膜中皮腫が疑われた1例
    南 和宏, 田中 雄悟, 中村 速, 黒田 紗菜恵, 松本 学, 光井 卓, 酒井 秀都, 木村 賢司, 岡本 武士, 清水 奈保子, 土井 健史, 法華 大助, 眞庭 謙昌, 神保 直江, 宮本 良文
    (NPO)日本肺癌学会, Apr. 2019, 肺癌, 59(2) (2), 210 - 211, Japanese

  • 重症筋無力症合併胸腺腫に対する手術症例の検討
    南和宏, 田中雄悟, 岡本武士, 清水奈保子, 土井健史, 法華大助, 神保直江, 眞庭謙昌
    2019, 日本胸部外科学会定期学術集会(Web), 72nd

  • in situ主体の悪性胸膜中皮腫が疑われた1例
    南和宏, 田中雄悟, 中村速, 黒田紗菜恵, 松本学, 光井卓, 酒井秀都, 木村賢司, 岡本武士, 清水奈保子, 土井健史, 法華大助, 眞庭謙昌, 神保直江, 宮本良文
    2019, 肺癌(Web), 59(2) (2)

  • 肺転移で診断された胸腺様分化を示す癌(ITET/CASTLE)の一例
    児玉貴之, 児玉貴之, 神保直江, 全陽, 伊藤智雄
    2018, 日本病理学会会誌, 107(1) (1)

  • てんかん発作で発症したMOG antibody associated encephalomyelitisの一例
    武中優, 千原典夫, 神保直江, 金子仁彦, 立花久嗣, 上田健博, Sekiguchi Kenji, 古和久朋, 苅田典生, 戸田達史
    Mar. 2017, 臨床神経学, 57(3号) (3号), 143, Japanese
    Meeting report

  • 腎腫瘤と肺嚢胞を認め,Birt-Hogg-Dube(BHD)症候群と遺伝子診断された3例
    田中宇多留, 末永裕子, 横山直己, 石村武志, 日向信之, 藤澤正人, 神保直江, 伊藤智雄, 高橋哲
    2016, 泌尿器画像診断・治療技術研究会プログラム・抄録, 4th

■ Books And Other Publications
  • 病理と臨床 骨軟部腫瘍の病理 I
    神保直江, 廣瀬隆則
    Contributor, 末梢神経鞘腫瘍の病理, Mar. 2020

  • 脳腫瘍臨床病理カラーアトラス / paraganglioma
    宇塚岳夫, Jimbo Naoe, 廣瀬隆則
    Others, 日本脳腫瘍病理学会, Oct. 2017, Japanese
    Textbook

■ Lectures, oral presentations, etc.
  • 重症アトピー性皮膚炎としてフォローされていたFolliculotropic mycosis fungoidesの1例
    木谷 美湖野, 江崎 諒, WASHIO KEN, ONO RYUSUKE, NISHIGORI CHIKAKO, 齊藤 泰之, JIMBO NAOE
    第470回 日本皮膚科学会 大阪地方会, Dec. 2018, Japanese, 大阪, Domestic conference
    Oral presentation

  • 縦隔発生の骨外性骨肉腫の一例
    岸田 雄治, OHNO YOSHIHARU, SEKI SHINICHIRO, JIMBO NAOE, ITO TOMOO, TANAKA YUGO, MANIWA YOSHIMASA, MURAKAMI TAKAMICHI
    第54回日本医学放射線学会秋季大会, Oct. 2018, Japanese, 日本医学放射線学会, 福岡, Domestic conference
    Oral presentation

  • 頭蓋内lymphomatoid granulomatosisの1例
    TANAKA KAZUHIRO, SASAYAMA TAKASHI, 藤田 祐一, 前山 昌博, JIMBO NAOE, ITO TOMOO, 廣瀬 隆則, KOHMURA EIJI
    第36回日本脳腫瘍病理学会, Sep. 2018, Japanese, 東京, Domestic conference
    Poster presentation

  • 頭蓋咽頭腫の悪性化と考えられた1例
    JIMBO NAOE, TANIGUCHI MASAAKI, HIROSE TAKANORI
    第36回日本脳腫瘍病理学会, Sep. 2018, Japanese, 東京, Domestic conference
    Poster presentation

  • グリア成分に増殖能亢進と核分裂像増加が見られたRosette-forming glioneuronal tumorの1例
    JIMBO NAOE, SASAYAMA TAKASHI, TANAKA KAZUHIRO, HIROSE TAKANORI
    第36回日本脳腫瘍病理学会, Sep. 2018, Japanese, 東京, Domestic conference
    Poster presentation

  • Lymphomatoid granulomatosis of the brain: A case report
    Kazuhiro Tanaka, Takashi Sasayama, Yuichi Fujita, Masahiro Maeyama, Naoe Jimbo, Tomoo Ito, Takanori Hirose, Eiji Kohmura
    The 19th international congress of neuropathology/The 36th Annual meeting of the Japan society of brain tumor pathology, Sep. 2018, English, 東京, International conference
    Poster presentation

  • Hybrid schwannoma/perineurioma is subclassified into mixed cellular and combined tumour types.
    Hirose Takanori, Kobayashi A, Jimbo Naoe, Nobusawa S
    The 30th European Congress of Pathology (ECP), 2018., Sep. 2018, English, Euskalduna, International conference
    Poster presentation

  • A rare case of craniopharyngioma with malignant transformation
    Naoe Jimbo, Masaaki Taniguchi, Takanori Hirose
    The 19th international congress of neuropathology/The 36th Annual meeting of the Japan society of brain tumor pathology, Sep. 2018, English, 東京, International conference
    Poster presentation

  • A case of rosette-forming glioneuronal tumor with an increased MIB-1 labeling index and mitotic figures in glial component
    Naoe Jimbo, Takashi Sasayama, Kazuhiro Tanaka, Takanori Hirose
    The 19th international congress of neuropathology/The 36th Annual meeting of the Japan society of brain tumor pathology, Sep. 2018, English, 東京, International conference
    Poster presentation

  • アレクチニブによる治療中に神経内分泌癌へ形質転換したと考えられたALK融合遺伝子陽性肺腺癌の一例
    小山貴与子, KATSURADA NAOKO, NAKATA KYOSUKE, 田村大介, NAGANO TATSUYA, YAMAMOTO MASATSUGU, TACHIHARA MOTOKO, KAMIRYO HIROSHI, KOBAYASHI KAZUYUKI, NISHIMURA YOSHIHIRO, JIMBO NAOE
    第91回 日本呼吸器学会, Jul. 2018, Japanese, 神戸, Domestic conference
    Oral presentation

  • 肺転移で診断された胸腺様分化を示す癌(ITET/CASTLE)の一例
    児玉 貴之, JIMBO NAOE, Quan Yang, ITO TOMOO
    第107回日本病理学会総会, 2018, Japanese, 札幌, Domestic conference
    Poster presentation

  • 乳児緊張性肺気腫の2例
    安福 正男, 岩出 珠幾, 曾田 洋輔, 久野 克也, 大西 徳子, 中尻 智史, 小寺 孝幸, 森沢 猛, 米谷 昌彦, JIMBO NAOE
    第55 回日本小児外科学会学術集会, 2018, Japanese, 新潟, Domestic conference
    Poster presentation

  • 同一患者由来の悪性黒色腫と正常色素細胞の遺伝子発現およびメチル化解析 ~診断マーカーとしてのNPM2の検討~
    FUJIWARA SUSUMU, 神保 晴紀, NAGAI HIROSHI, NISHIGORI CHIKAKO, JIMBO NAOE, 田中 朋代, 井家 益和
    第28回日本色素細胞学会学術大会, 2018, Japanese, 神戸, Domestic conference
    Oral presentation

  • 多形型脂肪肉腫様成分を有する後腹膜脱分化型脂肪肉腫の一例
    稲場 礼奈, ABE SHIHO, JIMBO NAOE, KANZAWA MAKI, ITO TOMOO, HIROSE TAKANORI
    第64回日本病理学会秋期特別総会, 2018, Japanese, 呉, Domestic conference
    Poster presentation

  • 診断に苦慮した肺動脈内進展型原発性肺癌の1切除例
    黒田 紗菜恵, 清水 奈保子, 岡本 武士, 土井 健史, 法華 大助, 田中 雄悟, JIMBO NAOE, 眞庭 謙昌
    第59回肺癌学会学術集会, 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 縦隔発生の骨外性骨肉腫の一例
    岸田 雄治, 大野 良治, 関 紳一郎, JIMBO NAOE, ITO TOMOO, 田中 雄悟, 真庭 謙昌, 村上 卓道
    第54回日本医学放射線学会秋季臨床大会, 2018, Japanese, 名古屋, Domestic conference
    Poster presentation

  • 細胞診検体でPD-L1免疫染色が可能か? 非小細胞肺癌の細胞診検体における検討
    立原 素子, 川嶋 雅也, 塚本 龍子, 和仁 洋治, JIMBO NAOE, 西村 善博
    第57回日本臨床細胞学会秋期大会, 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 胸腺非定型カルチノイドの2手術例
    光井 卓, 田中 雄悟, 岡本 武士, 清水 奈保子, 土井 健史, 法華 大助, JIMBO NAOE, 眞庭 謙昌
    第59回肺癌学会学術集会, 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 気管支喘息を背景にもつ肺原発MALTリンパ腫に対し外科的切除を行った1例
    中村 速, 土井 健史, 黒田 紗菜恵, 松本 学, 光井 卓, 酒井 秀都, 南 和宏, 木村 賢司, 岡本 武士, 清水 奈保子, 法華 大助, 田中 雄悟, JIMBO NAOE, 眞庭 謙昌
    第59回肺癌学会学術集会, 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • 気管支原性嚢胞由来と考えられた前縦隔平滑筋肉腫の一例
    岸田 雄治, 関 紳一郎, JIMBO NAOE, ITO TOMOO, 真庭 謙昌, 大野 良治
    第53回日本医学放射線学会秋季臨床大会, 2018, Japanese, 愛媛, Domestic conference
    Poster presentation

  • アレクチニブによる治療中に神経内分泌癌へ形質転換したと考えられたALK融合遺伝子陽性肺腺癌の一例
    小山 貴与子, 桂田 直子, 中田 恭介, 田村 大介, 永野 達也, 山本 正嗣, 立原 素子, 上領 博, 小林 和幸, 西村 善博, JIMBO NAOE
    第91回日本呼吸器学会近畿地方会, 2018, Japanese, 大阪, Domestic conference
    Oral presentation

  • アプローチに検討を要した巨大後縦隔脂肪肉腫の一例
    松本 学, 清水 奈保子, 岡本 武士, 土井 健史, 法華 大助, 田中 雄悟, JIMBO NAOE, 眞庭 謙昌
    第59回肺癌学会学術集会, 2018, Japanese, 横浜, Domestic conference
    Poster presentation

  • Low-grade fibromyxoid sarcoma(Evans tumor)の臨床病理学的検討 診断におけるFISHの有用性
    深瀬 直政, 藤田 郁夫, 河本 旭哉, 藤本 卓也, 佐久間 淑子, HIROSE TAKANORI, JIMBO NAOE, ITO TOMOO, 原 仁美, 秋末 敏宏, 黒田 良祐
    第91回日本整形外科学会学術総会, 2018, Japanese, 神戸, Domestic conference
    Poster presentation

  • Intimal sarcomaにおけるMDM2 dual-color ISHの有用性と限界
    JIMBO NAOE, KOMATSU MASATO, Quan Yang, HIROSE TAKANORI, ITO TOMOO
    第107回日本病理学会総会, 2018, Japanese, 札幌, Domestic conference
    Poster presentation

  • 副腎髄質過形成疑い病変に原発性副甲状腺機能亢進症を合併した一例
    中野 温子, Fukuoka Hidenori, Jimbo Naoe, 岩橋 泰幸, 古川 祥子, 亀村 幸平, 開發 謙次, Okada Yuko, Hirota Yushi, Iguchi Genzo, Ogawa Wataru, Takahashi Yutaka
    第27回臨床内分泌代謝Update, Nov. 2017, Japanese, 臨床内分泌代謝Update, 神戸, Domestic conference
    Poster presentation

  • Low-grade fibromyxoid sarcoma (Evans tumor)の 診断におけるFISHの有用性
    深瀬 直政, 藤田 郁夫, Kawamoto Teruya, 藤本 卓也, 佐久間 淑子, Hirose Takanori, Jimbo Naoe, Itoh Tomoo, Hara Hitomi, 森下 雅之, 蒲田 悦子, 片山 悦子, 竹森 俊幸, Akisue Toshihiro, Kuroda Ryosuke
    The 50th Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic Association, Jul. 2017, Japanese, The Japanese Orthopaedic Association, 東京, Domestic conference
    Oral presentation

  • 転移性胃腫瘍から診断 された左房内膜肉腫の1例
    中村 速, 迫 智也, 岡本典大, Jimbo Naoe, 有吉隆祐, 松岡晃生, 阪口博哉, 阿部洋文, 小原佳子, Tanaka Shinwa, Ishida Tsukasa, Morita Yoshinori, Toyonaga Takashi, Umegaki Eiji
    第98回日本消化器内視鏡学会近畿支部例会, Jun. 2017, Japanese, 日本消化器内視鏡学会近畿支部, 大阪, Domestic conference
    Oral presentation

  • 治療なく自然寛解と増悪を認めた中枢神経原発悪性リンパ腫の2例
    山口 陽二, Sasayama Takashi, Zen Yoh, Jimbo Naoe, 坂田 純一, 前山 昌博, Tanaka Kazuhiro, Itoh Tomoo, Hirose Takanori, Kohmura Eiji
    第35回日本脳腫瘍病理学会, May 2017, Japanese, 日本脳腫瘍病理学会, 宇都宮市, Domestic conference
    Poster presentation

  • Rosette-forming glioneuronal tumor (RGNT)の2症例
    前山 昌博, Sasayama Takashi, Jimbo Naoe, Hara Shigeo, Tanaka Kazuhiro, 荒井 篤, 大林 千穂, Itoh Tomoo, Hirose Takanori, Kohmura Eiji
    第35回日本脳腫瘍病理学会, May 2017, Japanese, 日本脳腫瘍病理学会, 宇都宮市, Domestic conference
    Poster presentation

  • Low-grade fibromyxoid sarcoma (Evans tumor)の診断における分子遺伝学的解析の有用性
    深瀬 直政, 藤田 郁夫, Kawamoto Teruya, 藤本 卓也, 佐久間 淑子, Hirose Takanori, 須藤 保, Jimbo Naoe, Itoh Tomoo, Hara Hitomi, Akisue Toshihiro, Kuroda Ryosuke
    The 90th Annual Meetin of the Japanese Orthopaedic Association, May 2017, Japanese, The Japanese Orthopaedic Association, 仙台, Domestic conference
    Poster presentation

  • 腎腫瘤と肺嚢胞を認め、Birt-Hogg-Dubé (BHD)症候群と遺伝子診断された2例
    田中宇多留, Ueno Yoshiko, Takahashi Satoru, 杉村 和朗, 横山 直己, Ishimura Takeshi, Hinata Nobuyuki, 横山 直己, Ishimura Takeshi, Hinata Nobuyuki, Fujisawa Masato, Jimbo Naoe, Itoh Tomoo
    第314回日本医学放射線学会関西地方会, Nov. 2016, Japanese, 日本医学放射線学会, 大阪, Domestic conference
    Oral presentation

  • てんかん発作で発症した MOG antibody associated encephalomyelitisの一例
    武中 優, Chihara Norio, Jimbo Naoe, 金子 仁彦, Tachibana Hisatsugu, Ueda Takehiro, Sekiguchi Kenji, Kowa Hisatomo, Kanda Fumio, Toda Tatsushi
    日本神経学会第106回近畿地方会, Nov. 2016, Japanese, 日本神経学会, 京都, Domestic conference
    Oral presentation

  • Clinicopathological investigation of low-grade fibromyxoid sarcoma (Evans tumor)
    Naomasa Fukase, Ikuo Fujita, Kawamoto Teruya, Toshiko Sakuma, Hirose Takanori, Jimbo Naoe, Tomoo Itoe, Hara Hitomi, Takuya Fujimoto, Masayuki Morishita, Etsuko Kamata, Toshiyuki Takemori, Kuroda Ryosuke, Akisue Toshihiro
    2016 Connective Tissue Oncology Society Annual Meeting, Nov. 2016, English, Connective Tissue Oncology Socisty, Lisbon, Portugal, International conference
    Poster presentation

  • 肺結節切除標本にびまん性特発性神経内分泌細胞過形成を認めた1例
    酒井 秀都, 松本 高典, 内田 孝宏, 金 泰雄, 木村 賢司, Shimizu Nahoko, Ogawa Hiroyuki, Hokka Daisuke, Tanaka Yugo, 真庭 謙昌, Jimbo Naoe, Sakai Yasuhiro
    第104回日本肺癌学会関西支部会, Jul. 2016, Japanese, 日本肺癌学会, 大阪, Domestic conference
    Poster presentation

  • 悪性黒色腫の肺転移と思われた1例
    Jimbo Naoe, 大谷 恭子, Sakai Yasuhiro, 川本 めぐみ, 羽間 大祐, 堂國 良太, 吉崎 飛鳥, 桐生 辰徳, 関谷 怜奈, 寺下 智美, 梅澤 佳乃子, 尾野 慶彦, 三輪 菜々子, 桂田 雅大, 徳永 俊太郎, 桂田 直子, 田村 大介, Nagano Tatsuya, Nakata Kyosuke, Yamamoto Masatsugu, Tachihara Motoko, Kobayashi Kazuyuki, Nishimura Yoshihiro, 酒井 秀都, 内田 孝宏, 金 泰雄, 木村 賢司, Shimizu Nahoko, Ogawa Hiroyuki, 法華 大介, Tanaka Yugo, Maniwa Yoshimasa, Ohno Yoshiharu
    第104回日本肺癌学会関西支部会, Jul. 2016, Japanese, 日本肺癌学会, 大阪, Domestic conference
    Poster presentation

  • 急速な心筋障害を呈した若年のTAFRO症候群の一例
    白井 太一朗, 脇 大輔, 千藤 荘, 市川 晋也, 山本 譲, Akashi Kengo, Onishi Akira, Kogata Yoshinori, Saegusa Jun, Jimbo Naoe, Morinobu Akio
    第45回神戸免疫・膠原病懇話会, Jun. 2016, Japanese, 神戸免疫・膠原病懇話会, 神戸, Domestic conference
    Oral presentation

  • 肝血管筋脂肪腫におけるTFE3遺伝子異常
    Jimbo Naoe, 西上隆之, 野口雅之, 廣田誠一, 田尻琢磨, 井上健, Zen Yoh, Hirose Takanori, Itoh Tomoo
    第105回日本病理学会総会, May 2016, Japanese, 日本病理学会, 仙台, Domestic conference
    Poster presentation

  • Fibrous dysplasiaとの鑑別を要したodontogenic carcinomaの1例
    平井千浦子, Jimbo Naoe, Morinaga Yukiko, Hirose Takanori, 廣瀬勝俊, 岸野万伸, 豊澤悟, 小川郁子, 高田隆, Itoh Tomoo
    第105回日本病理学会総会, May 2016, Japanese, 日本病理学会, 仙台, Domestic conference
    Poster presentation

  • Diagnostic utility and limitation of immunohistochemistry and DISH in dedifferentiated liposarcoma
    小林杏奈, 佐久間淑子, 梶本和義, 前田尚子, 高橋祐一, 藤本昌代, Jimbo Naoe, Hirose Takanori
    第105回日本病理学会総会, May 2016, English, 日本病理学会, 仙台, Domestic conference
    Oral presentation

■ Research Themes
  • 阪神地域の胸水貯留患者への胸水細胞診を用いた早期中皮腫の同定に関する研究
    河原 邦光, 神保 直江
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2023 - 31 Mar. 2026

  • Elucidation of the pathogenic mechanism and reconsideration of treatment of combined small cell carcinoma
    神保 直江
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists, Grant-in-Aid for Early-Career Scientists, Kobe University, 01 Apr. 2022 - 31 Mar. 2025

  • 新たな亜型分類に基く肺高悪性度神経内分泌癌の新規予後マーカー探索と個別化治療確立
    神保 直江
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists, Grant-in-Aid for Early-Career Scientists, Kobe University, 01 Apr. 2019 - 31 Mar. 2022

  • Epigenomic analysis of malignant melanoma and examination of biomarkers in immunotherapy
    Fujiwara Susumu, NISHIGORI chikako, NAGAI hiroshi, JIMBO haruki, JIMBO naoe, INOIE masukazu, TANAKA tomoyo
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B), Grant-in-Aid for Young Scientists (B), Kobe University, 01 Apr. 2017 - 31 Mar. 2019
    DNA methylation is considered the primary epigenetic mechanism underlying the development of malignant melanoma. Since DNA methylation can be influenced by environmental factors, it is preferable to compare cancer and normal cells from the same patient. We employed a novel epidermal sheet cultivation technique to isolate normal melanocytes from unaffected sites of melanoma patients. Our analysis discovered methylation at several novel loci (KRTCAP3, AGAP2, ZNF490). Subsequent studies revealed that NPM2 was hypermethylated and downregulated in melanomas. In many normal melanocytes, NPM2 showed distinct immunohistochemical staining, while its expression was lost in malignant melanoma cells. In particular, intraepithelial lesions of malignant melanoma, an important challenge in clinical practice, could be distinguished from benign nevi. NPM2 immunoreactivity could be used to differentiate melanomas from normal melanocytes or benign disease.

TOP